Biotechnology

A patient with 'untreatable' colorectal cancer is disease-free for six years after a novel vaccine. But the real revolution may be the biopsy-free tech behind it.

A new clinical trial for a sacroiliac joint device isn't just about technology; it's about a company's bet that rigorous evidence is the best medicine for patients and the healthcare system.

A Cambridge startup is building a 'Common Crawl for the living world,' framing biological data as a strategic weapon in the US-China tech rivalry.

A new Philips report quantifies AI's benefits in healthcare, from saving time to catching errors. But the path to adoption is fraught with challenges.

Millions suffer from Dry Eye Disease with few good options. A new clinical trial is now testing a drug tailored to a patient's DNA. Is this the end of trial-and-error?

FloBiotech and UCLA Health are betting on a new strategy against neurodegeneration: boosting the brain's own defenses. This alliance could redefine a field long plagued by failure.

As a deadly Ebola strain spreads without a vaccine, Dr. Patrick Soon-Shiong's foundation injects $10M and shifts its strategy to direct African aid.

A major study combining two powerful cancer drugs, KEYTRUDA and Trodelvy, has been halted, a setback for patients and a reality check for the industry.

Following its Ouro Medicines acquisition, Lakefront appoints veteran Eric Hedrick as CMO to drive its new immunology pipeline, signaling a bold transformation.

New data on elecoglipron, an oral pill with no food restrictions, shows major weight loss and A1C reduction, positioning AstraZeneca to disrupt the GLP-1 market.

A new fellowship from Wave and Conservation Nation goes beyond the check, building a global network of innovators to tackle the ocean's biggest crises.

New data on Eli Lilly's oral GLP-1, orforglipron, shows superior results over rivals, promising a new era for millions of needle-averse patients.

New research from Baycrest unmasks paratonia, an involuntary condition often mistaken as defiance, signaling a seismic shift in dementia care and treatment.

As Capricor presents its late-stage DMD drug and novel exosome platform, can it convince investors it has the key to both patient impact and market success?

An aging world and failing antibiotics are driving a surge in pneumonia. Now, a new generation of therapies is being built to fight back. Here's how.

With key hires Ulf Wiinberg and Bill MacKenzie, Neuraptive signals a major shift from R&D to market readiness for its nerve repair therapeutic, NTX-001.

A Stanford spinout just revealed a wearable that measures the body's master stress hormone in real time. This isn't just a new gadget; it's a fundamental shift.

A small Canadian firm is partnering with the nation's top research body to turn a unique Greenlandic mineral into a powerful new tool for CO2 removal.

Conexeu Sciences hits a key manufacturing milestone for its innovative wound-healing gel, but the path to FDA clearance and a crowded market remains a challenge.

A landmark drug approval in China offers new hope for IgAN patients. But the real story is how science, strategy, and policy are converging to build a better future.